These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 10986736)

  • 21. The changing and dynamic epidemiology of meningococcal disease.
    Halperin SA; Bettinger JA; Greenwood B; Harrison LH; Jelfs J; Ladhani SN; McIntyre P; Ramsay ME; Sáfadi MA
    Vaccine; 2012 May; 30 Suppl 2():B26-36. PubMed ID: 22178525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alternative vaccine strategies to prevent serogroup B meningococcal diseases.
    Poolman J; Berthet FX
    Vaccine; 2001 Oct; 20 Suppl 1():S24-6. PubMed ID: 11587805
    [No Abstract]   [Full Text] [Related]  

  • 23. Epidemiology of invasive meningococcal disease in Germany, 2002-2010, and impact of vaccination with meningococcal C conjugate vaccine.
    Hellenbrand W; Elias J; Wichmann O; Dehnert M; Frosch M; Vogel U
    J Infect; 2013 Jan; 66(1):48-56. PubMed ID: 23043893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine.
    de Whalley PC; Snape MD; Kelly DF; Banner C; Lewis S; Diggle L; John TM; Yu LM; Omar O; Borkowski A; Pollard AJ
    Pediatr Infect Dis J; 2011 Nov; 30(11):e203-8. PubMed ID: 21673612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Meningococcal vaccines. Global epidemiological situation and strategies for prevention by vaccination].
    Rivero Calle I; Rodriguez-Tenreiro Sánchez C; Martinón-Torres F
    Enferm Infecc Microbiol Clin; 2015 Apr; 33(4):257-67. PubMed ID: 25795150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outbreaks of group B meningococcal disease--Florida, 1995 and 1997.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1998 Oct; 47(39):833-7. PubMed ID: 9780239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serogroup C meningococcal outbreaks in the United States. An emerging threat.
    Jackson LA; Schuchat A; Reeves MW; Wenger JD
    JAMA; 1995 Feb; 273(5):383-9. PubMed ID: 7823383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meningococcal disease: the advances and challenges of meningococcal disease prevention.
    Yogev R; Tan T
    Hum Vaccin; 2011 Aug; 7(8):828-37. PubMed ID: 21832882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Challenges for development of meningococcal vaccines in infants and children.
    Deasy A; Read RC
    Expert Rev Vaccines; 2011 Mar; 10(3):335-43. PubMed ID: 21434801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Confronting the Epidemiology, Burden, Treatment, and Prevention of Meningococcal Disease.
    Middleman AB; Zimet GD
    J Adolesc Health; 2016 Aug; 59(2 Suppl):S1-2. PubMed ID: 27449144
    [No Abstract]   [Full Text] [Related]  

  • 31. Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification.
    Garrido-Estepa M; León-Gómez I; Herruzo R; Cano R
    Vaccine; 2014 May; 32(22):2604-9. PubMed ID: 24662700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines.
    Ladhani SN; Flood JS; Ramsay ME; Campbell H; Gray SJ; Kaczmarski EB; Mallard RH; Guiver M; Newbold LS; Borrow R
    Vaccine; 2012 May; 30(24):3710-6. PubMed ID: 22429756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined Haemophilus Influenzae type B-Neisseria meningitidis serogroup C vaccine is immunogenic and well tolerated in preterm infants when coadministered with other routinely recommended vaccines.
    Omeñaca F; Arístegui J; Tejedor JC; Moreno-Perez D; Ruiz-Contreras J; Merino JM; Muro Brussi M; Sánchez-Tamayo T; Castro Fernandez J; Cabanillas L; Peddiraju K; Mesaros N; Miller JM
    Pediatr Infect Dis J; 2011 Nov; 30(11):e216-24. PubMed ID: 21747321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meningococcal disease among United States military service members in relation to routine uses of vaccines with different serogroup-specific components, 1964-1998.
    Brundage JF; Ryan MA; Feighner BH; Erdtmann FJ
    Clin Infect Dis; 2002 Dec; 35(11):1376-81. PubMed ID: 12439801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Present situation and new perspectives for vaccination against Neisseria meningitidis in Tuscany, Central Italy.
    Bechini A; Levi M; Boccalini S; Tiscione E; Ceccherini V; Taddei C; Balocchini E; Bonanni P
    J Prev Med Hyg; 2012 Jun; 53(2):61-7. PubMed ID: 23240162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidemic meningococcal disease in sub-Saharan Africa--towards a sustainable solution?
    Pollard AJ; Maiden MC
    Lancet Infect Dis; 2003 Feb; 3(2):68-70. PubMed ID: 12560188
    [No Abstract]   [Full Text] [Related]  

  • 38. Epidemiology of pathogenic Neisseria meningitidis serogroup B serosubtypes in Malta: implications for introducing PorA based vaccines.
    Pace D; Cuschieri P; Galea Debono A; Attard-Montalto S
    Vaccine; 2008 Nov; 26(47):5952-6. PubMed ID: 18801401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meningococcal vaccines: Current state and future outlook.
    Leca M; Bornet C; Montana M; Curti C; Vanelle P
    Pathol Biol (Paris); 2015 Jun; 63(3):144-51. PubMed ID: 25986879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination.
    de Whalley PC; Snape MD; Plested E; Thompson B; Nuthall E; Omar O; Borrow R; Pollard AJ
    Arch Dis Child; 2013 Sep; 98(9):686-91. PubMed ID: 23853000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.